Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Touchlight Genetics Ltd
Touchlight Genetics Ltd
Activities:
Pharmaceutical
X
LinkedIn
Trending Articles
LUNA 3: Rilzabrutinib Phase III immune thrombocytopenia trial meets primary endpoint
Rilzabrutinib met both the primary endpoint of durable platelet response and various secondary endpoints in patients who were refractory to prior therapy
Fasenra for EGPA: addressing unmet needs
Benralizumab could offer patients with EGPA more treatment options, while reducing dependency on oral corticosteroids
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success
Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...
Bristol Myers Squibb and Cellares partner to expand CAR-T manufacturing capabilities
Cellares will optimise and automate select Bristol Myers Squibb CAR-T cell therapies onto its high-throughput manufacturing program, the Cell Shuttle
Upcoming event
Cleanroom Conference UK
22–23 May 2024 | Exhibition | Birmingham, UK
See all
Related Content
Research & Development
Touchlight’s dbDNA to be used in neoantigen cancer vaccine trial
The dbDNA technology will be used in the development of a non-small cell lung cancer vaccine
Cell & Gene Therapy
Touchlight awarded tender to supply enzymatic dbDNA to CPI
CPI has selected Touchlight to supply research and GMP-grade enzymatic DNA for the development and manufacturing of RNA therapeutics and vaccines
Research & Development
Curia expands biologics capabilities with access to Touchlight’s doggybone DNA
Curia collaborates with Touchlight to expand its mRNA manufacturing offering to enable access to enzymatic doggybone DNA (dbDNA)
Manufacturing
Touchlight creates giant London DNA manufacturing facility
Facility will have capacity that exceeds today’s global plasmid DNA demand and can enable commercialisation of genetic medicines
Regulatory
FDA signs off Touchlight's Drug Master File
The acceptance of the DMF for GMP grade dbDNA will ensure that customers no longer need to prepare a standalone section in their fillings
Digital
Touchlight signs DNA technology license agreement with Voyager
Touchlight’s enzymatically amplified doggybone DNA technology enables the rapid and scalable amplification of DNA regardless of sequence length or complexity
Manufacturing
Lonza announces Touchlight collaboration on end-to-end mRNA
Lonza will have the ability to integrate an additional source of DNA in its end-to-end offering to customers developing messenger RNA therapeutics and vaccines
Subscribe now